BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 15827168)

  • 41. Cross-subtype T-cell immune responses induced by a human immunodeficiency virus type 1 group m consensus env immunogen.
    Weaver EA; Lu Z; Camacho ZT; Moukdar F; Liao HX; Ma BJ; Muldoon M; Theiler J; Nabel GJ; Letvin NL; Korber BT; Hahn BH; Haynes BF; Gao F
    J Virol; 2006 Jul; 80(14):6745-56. PubMed ID: 16809280
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
    Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ;
    J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hemagglutinating virus of Japan protein is efficient for induction of CD4+ T-cell response by a hepatitis B core particle-based HIV vaccine.
    Takeda S; Shiosaki K; Kaneda Y; Nakasatomi T; Yoshizaki H; Someya K; Konno Y; Eda Y; Kino Y; Yamamoto N; Honda M
    Clin Immunol; 2004 Jul; 112(1):92-105. PubMed ID: 15207786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A recombinant live attenuated measles vaccine vector primes effective HLA-A0201-restricted cytotoxic T lymphocytes and broadly neutralizing antibodies against HIV-1 conserved epitopes.
    Lorin C; Delebecque F; Labrousse V; Da Silva L; Lemonnier F; Brahic M; Tangy F
    Vaccine; 2005 Aug; 23(36):4463-72. PubMed ID: 15993518
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of canarypox-induced CD8(+) responses following immunization by measuring the effector population IFNgamma production.
    Evans TG; Kallas EG; Campbell M; Andrews J; Schwartz D; Keefer M; Caudrelier P
    Immunol Lett; 2001 May; 77(1):7-15. PubMed ID: 11348664
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
    Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.
    Wild J; Bojak A; Deml L; Wagner R
    Vaccine; 2004 Apr; 22(13-14):1732-43. PubMed ID: 15068857
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
    Evans TG; Keefer MC; Weinhold KJ; Wolff M; Montefiori D; Gorse GJ; Graham BS; McElrath MJ; Clements-Mann ML; Mulligan MJ; Fast P; Walker MC; Excler JL; Duliege AM; Tartaglia J
    J Infect Dis; 1999 Aug; 180(2):290-8. PubMed ID: 10395842
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag.
    Zhao J; Voltan R; Peng B; Davis-Warren A; Kalyanaraman VS; Alvord WG; Aldrich K; Bernasconi D; Buttò S; Cafaro A; Ensoli B; Robert-Guroff M
    Virology; 2005 Nov; 342(1):1-12. PubMed ID: 16109434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity of recombinant Modified Vaccinia Ankara Viruses (rMVA) expressing HIV-1 Indian subtype C gag-protease and env-gp120 genes in mice.
    Kumar S; Seth P
    Viral Immunol; 2004; 17(4):574-9. PubMed ID: 15671754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus.
    Xin KQ; Urabe M; Yang J; Nomiyama K; Mizukami H; Hamajima K; Nomiyama H; Saito T; Imai M; Monahan J; Okuda K; Ozawa K; Okuda K
    Hum Gene Ther; 2001 Jun; 12(9):1047-61. PubMed ID: 11399227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.
    Kanekiyo M; Matsuo K; Hamatake M; Hamano T; Ohsu T; Matsumoto S; Yamada T; Yamazaki S; Hasegawa A; Yamamoto N; Honda M
    J Virol; 2005 Jul; 79(14):8716-23. PubMed ID: 15994765
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human immunodeficiency virus-like particles activate multiple types of immune cells.
    Sailaja G; Skountzou I; Quan FS; Compans RW; Kang SM
    Virology; 2007 Jun; 362(2):331-41. PubMed ID: 17276476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001).
    Barouch DH; Liu J; Peter L; Abbink P; Iampietro MJ; Cheung A; Alter G; Chung A; Dugast AS; Frahm N; McElrath MJ; Wenschuh H; Reimer U; Seaman MS; Pau MG; Weijtens M; Goudsmit J; Walsh SR; Dolin R; Baden LR
    J Infect Dis; 2013 Jan; 207(2):248-56. PubMed ID: 23125443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.
    Wyatt LS; Earl PL; Vogt J; Eller LA; Chandran D; Liu J; Robinson HL; Moss B
    Vaccine; 2008 Jan; 26(4):486-93. PubMed ID: 18155813
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice.
    Bruce CB; Akrigg A; Sharpe SA; Hanke T; Wilkinson GWG; Cranage MP
    J Gen Virol; 1999 Oct; 80 ( Pt 10)():2621-2628. PubMed ID: 10573155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteins.
    Quan FS; Sailaja G; Skountzou I; Huang C; Vzorov A; Compans RW; Kang SM
    Vaccine; 2007 May; 25(19):3841-50. PubMed ID: 17320250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.
    Caley IJ; Betts MR; Irlbeck DM; Davis NL; Swanstrom R; Frelinger JA; Johnston RE
    J Virol; 1997 Apr; 71(4):3031-8. PubMed ID: 9060663
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.
    Wanjalla CN; Faul EJ; Gomme EA; Schnell MJ
    Vaccine; 2010 Dec; 29(1):130-40. PubMed ID: 20728525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.